KEI Briefing Note 2018:1. Bayh-Dole Obligations to Disclose Federal Funding in Patented Inventions
Access to Medicine
Malaysia . March 14, 2018 Letter to USTR re Malaysia Special 301
These were KEI comments to USTR regarding PhRMA’s efforts to target Malaysia as a Priority Foreign Country for issuing a compulsory license on sofosbuvir patents. Malaysia.14March2018.KEI.USTR.Special 301 March 14, 2018 The Honorable Robert Lighthizer United States Trade Representative Executive Office… Continue Reading
13 NGOs Call on USTR To Support Colombia in Special 301 Following Pressure Over Legal Access to Meds Efforts
KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading
EC publishes report on protection and enforcement of intellectual property rights in “third countries”
On March 12, 2018, the European Commission issued a press release on a report on the “protection and enforcement of intellectual property rights in third countries”. The report was published on February 21, 2018 and is entitled – “Commission Staff… Continue Reading
KEI request that HHS take ownership of US Patent 7,964,580 on sofosbuvir, now held by Gilead, for non-disclosure of NIH grants
In the attached letter dated March 14, 2018 to Secretary of the Department of Health and Human Services (DHHS) Alex Azar, KEI is asking for an investigation into a failure to report NIH funding on US patent 7,964,580. This is… Continue Reading
Coalition calls on US and Korea Trade Negotiators to prioritize public health over pharma corporations in trade negotiations
FOR IMMEDIATE RELEASE March 12, 2018 kim.treanor@keionline.org (202)-332-2670 A coalition of 16 advocacy organizations in the United States and Korea asked trade negotiators in the U.S. and Korea to reject the demands of the pharmaceutical industry, protect human rights, and… Continue Reading
Chile Ministry of Health Takes Next Step Toward Compulsory License on HCV Drugs, Announces Public Health Justifications
In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV),… Continue Reading
KEI testimony at March 8, 2018 USTR Special 301 hearing, focusing on US compulsory licensing of patents
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading
Innogenetics v. Abbott – 2008 compulsory license granted for HCV genotyping kits under eBay v. MercExchange
This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading
Statement of Portugal: UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030
On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030… Continue Reading